23.22
+0.71(+3.15%)
Currency In USD
| Previous Close | 22.51 |
| Open | 22.12 |
| Day High | 24 |
| Day Low | 21.21 |
| 52-Week High | 24.99 |
| 52-Week Low | 10 |
| Volume | 107,207 |
| Average Volume | 42,758 |
| Market Cap | 163.62M |
| PE | -0.97 |
| EPS | -23.9 |
| Moving Average 50 Days | 15.91 |
| Moving Average 200 Days | 13.68 |
| Change | 0.71 |
If you invested $1000 in Cidara Therapeutics, Inc. (CDTX) since IPO date, it would be worth $1,451.25 as of December 22, 2024 at a share price of $23.22. Whereas If you bought $1000 worth of Cidara Therapeutics, Inc. (CDTX) shares 5 years ago, it would be worth $9,141.73 as of December 22, 2024 at a share price of $23.22.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cidara Therapeutics Completes Enrollment of Phase 2b NAVIGATE Trial Evaluating CD388 for Prevention of Seasonal Influenza
GlobeNewswire Inc.
Dec 04, 2024 1:00 PM GMT
SAN DIEGO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the stan
Cidara Therapeutics Announces $105 Million Private Placement
GlobeNewswire Inc.
Nov 21, 2024 1:30 PM GMT
Financing led by new investor, Venrock Healthcare Capital Partners, with significant participation by new and existing life sciences-focused investorsSAN DIEGO, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechno
Cidara Therapeutics to Participate in Evercore 7th Annual HealthCONx Conference
GlobeNewswire Inc.
Nov 19, 2024 1:00 PM GMT
SAN DIEGO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the stan